TheraBite治疗急性肌源性颞下颌关节紊乱病的成本效益分析数据集

数据集获取（Figshare）

• 源站标题：The cost-effectiveness of TheraBite® as treatment for acute myogenic temporomandibular disorder
• DOI：10.6084/m9.figshare.3830439.v1
• 发布日期：2016-09-15
• 文件数：5 个
• 文件总体积：636.56 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/The_cost-effectiveness_of_TheraBite_as_treatment_for_acute_myogenic_temporomandibular_disorder/3830439

命令行下载

curl -L -o "Supplemental material.doc" "https://ndownloader.figshare.com/files/5976672"
curl -L -o "SupplementalFigure1_DecisionTree.jpg" "https://ndownloader.figshare.com/files/5976675"
curl -L -o "SupplementalFigure2_CCA.jpg" "https://ndownloader.figshare.com/files/5976678"
curl -L -o "SupplementalFigure3_Tornado.jpg" "https://ndownloader.figshare.com/files/5976681"
curl -L -o "SupplementalTable1_PatientCharacteristicsOutcomeMeasurements.docx" "https://ndownloader.figshare.com/files/5976684"

文件清单

• Supplemental material.doc（34.82 KB）
• SupplementalFigure1_DecisionTree.jpg（430.05 KB）
• SupplementalFigure2_CCA.jpg（64.93 KB）
• SupplementalFigure3_Tornado.jpg（92.64 KB）
• SupplementalTable1_PatientCharacteristicsOutcomeMeasurements.docx（14.13 KB）

文件总体积 636.56 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Objective: Temporomandibular disorder (TMD) is a very common and costly pain problem concerning the temporomandibular joint. A previous study has shown that for the treatment of acute myogenic TMD, TheraBite® (TB) offers a faster and greater effect than usual care consisting of physical therapy (PT). This study estimates the cost-effectiveness of TB compared to PT.
Methods: Differences in costs and quality-adjusted life-years (QALYs) between TB and PT are analyzed using a decision model.
Results: The point estimate for the incremental cost-effectiveness ratio is −28,068 EUR (−30,191 USD) per QALY (dominant) for TB versus PT. At the willingness-to-pay ratio of 20,000 EUR (21,513 USD) per QALY, TB has a 97% probability of being cost-effective compared to PT.
Conclusion: TB is expected to be cost-effective compared to PT for the treatment of acute myogenic TMD, offering faster recovery of quality of life for patients, at a lower cost to society.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.3830439.v1（source: https://tandf.figshare.com/articles/dataset/The_cost-effectiveness_of_TheraBite_as_treatment_for_acute_myogenic_temporomandibular_disorder/3830439）。